Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 29/11/2020
SIETES contiene 93170 citas

 
 
 1 a 12 de 12 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Pease AM, Krumholz HM, Hines HH, Downing NS, Aminawung JA, Shah ND, Ross JS. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. BMJ 2017;357:j1680. [Ref.ID 101573]
2. Cita con resumen
Downing NS, Shah ND, Aminawung JA, Pease AM, Zeitoun JD, Krumholz HM, Ross JS. Postmarket safety events among novel therapeutics approved by the US Food and Drug Administration between 2001 and 2010. JAMA 2017;317:1854-63. [Ref.ID 101567]
3. Cita con resumen
Lipska KJ, Yao X, Herrin J, McCoy RG, Ross JS, Steinman MA, Inzucchi SE, Gill TM, Krumholz HM, Shah ND. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care 2017;40:468-75. [Ref.ID 101507]
4. Cita con resumen
Lipska KJ, Yao X, Herrin J, McCoy RG, Ross JS, Steinman MA, Inzucchi SE, Gill TM, Krumholz HM, Shah ND. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care 2016:septiembre. [Ref.ID 100915]
5.Tiene citas relacionadas Cita con resumen
Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, Shah ND. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ 2015;350:h1857. [Ref.ID 98978]
6.Enlace a cita original Cita con resumen
Lipska KJ, Ross JS, MIao Y, Shah ND, Lee SJ, Steinman MA. Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Intern Med 2015;175:356-62. [Ref.ID 98764]
7.
Downing NS, Aminawung JA, Shah ND, Braunstein JB, Krumholz HM, Ross JS. Regulatory review of novel therapeutics - Comparison of three regulatory agencies. N Engl J Med 2012;366:2284-93. [Ref.ID 93211]
8. Cita con resumen
Jackevicius CA, Chou MM, Ross JS, Shah ND, Krumholz HM. Generic atorvastatin and health care costs. N Engl J Med 2012;366:201-4. [Ref.ID 92233]
9.Tiene citas relacionadas
Montori VM, Shah ND. What have we learnt from the rosiglitazone saga?. BMJ 2011;342:666. [Ref.ID 90337]
10. Cita con resumen
Shah ND, Montori VM, Krumholz HM, Tu K, Alexander GC, Jackevicius CA. Responding to an FDA warning - Geographic variation in the use of rosiglitazone. N Engl J Med 2010;363:2081-4. [Ref.ID 89710]
11. Cita con resumen
Mullan RJ, Montori VM, Shah ND, Christianson TJH, Bryant SC, Guyatt GH, Perestelo-Perez LI, Stroebel RJ, Yawn BP, Yapuncich V, Breslin MA, Pencille L, Smith SA. The diabetes mellitus medication choice decision aid. A randomized trial. Arch Intern Med 2009;169:1560-8. [Ref.ID 86843]
12. Cita con resumen
Fazel R, Krumholz HM, Wang Y, Ross JS, Chen J, Ting HH, Shah ND, Nasir K, Einstein AJ, Nallamothu BK. Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med 2009;361:849-57. [Ref.ID 86655]
Seleccionar todas
 
 1 a 12 de 12